Multidrug resistance gene (MDR1) - marker of therapeutic resistance and severity of disease



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Genes polymorphism is known to be one of the causes of the inadequate response to drugs or drugs resistance. In the most of cases drugs influence depends on interaction of several products of genes expression, which influence on drugs pharmacokinetics and pharmacodynamics.
Present article concerns the review of publications and results of original investigations concerning the multidrug resistance gene (MDRl) expression associations with P-glycoprotein-170 (Pgp-170) expression in different diseases and the role of Pgp-170 in distribution of drugs in tissues.

About the authors

Z A Mironova

Department of Hospital Therapy, LP. Pavlov State Medical University

Email: zhanmir@mail.ru
Department of Hospital Therapy, LP. Pavlov State Medical University

V I Trofimov

Department of Hospital Therapy, LP. Pavlov State Medical University

Department of Hospital Therapy, LP. Pavlov State Medical University

M A Simakova

Department of Hospital Therapy, LP. Pavlov State Medical University

Department of Hospital Therapy, LP. Pavlov State Medical University

E D Iantchina

Department of Molecule and Gene Technologies, LP. Pavlov State Medical University

Department of Molecule and Gene Technologies, LP. Pavlov State Medical University

M V Dubina

Department of Molecule and Gene Technologies, LP. Pavlov State Medical University

Department of Molecule and Gene Technologies, LP. Pavlov State Medical University

References

  1. Vesell J. Advances in pharmacogenetics and pharmacoge-nom-ics. Clin. Pharmacol. 2000, v. 40, p. 930-938.
  2. Середенин СБ. Лекции по фармакогенетике. М., «Медицинское информационное агентство». 2004, с. 36.
  3. Miklos Bodor, Edward J. Kelly, Rodney J. Ho. Characterization of the Human MDR1 Gene. The AAPS Journal. 2005, v. 07(01), p. 1-5.
  4. Hoffmeyer S., Burk O., Richter O. et al. Functional polymorphisms of the human multidrug resistance gene: Multiple sequence variations and correlation of one allele with P-glyco-protein expression and activity in vivo. Proc. Natl. Acad. Sci. USA. 2000, v. 97, p. 3473-3478.
  5. Mark J. Dresser. The MDR1 C3435T Polymorphism: Effects on P-glycoprotein Expression/Function and Clinical Significance. AAPS Pharm Sci. 2001, v. 3, p. 3.
  6. FarrellR.O., KelleherD. Glucocorticoid resistance in inflammatory bowel disease. Journal of Endocrinology. 2003, v. 178, p. 339-346.
  7. Hauser LA., Schaeffeler E., Gauer S. et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J. Am. Soc. Nephrol. 2005, v. 16, p. 1501-1511.
  8. Asano T, Takahashi K.A, Fujioka M. et al. ABCB1 C3435T and G2677TWA polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics. 2003, v. 13, p.675-682.
  9. Zheng H., Webber S., Zeevi A. et al. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum. Immunol. 2002, v. 63, p. 765-770.
  10. Turgut S., Yaren A., Kursunluoglu R., Turgut G. MDR1 C3435T polymorphism in patients with breast cancer. Arch. Med. Res. 2007, v. 38 (5), p. 539-44.
  11. Zheng H.X., Zeevi A., McCurry K., Schuetz E. et al. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl. Immunol. 2005, v. 14(1), p. 37-42.
  12. Schwab M., Schaeffeler E., MarxC. etal. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology. 2003, v. 124, p. 26-33.
  13. Ho G.T., Nimmo E.R., Tenesa A. et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology, 2005, v. 128, p. 288-296.
  14. Croucher P.J., Mascheretti S., Foelsch U.R. et al. Lack of association between the C3435 MDR1 gene polymorphisms and inflammatory bowel disease in two independent Northern European populations. Gastroenterology. 2003, v. 125, p. 1919-1920.
  15. Glas J., Torok H.R, Schiemann U., Folwaczny С MDR1 gene polymorphism in ulcerative colitis. Gastroenterology. 2004, v. 126, p. 367.
  16. PalmieriO., LatianoA., Valvano R. etal. Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment Pharmacol Ther. 2005, v. 22, p. 1129-1138.
  17. Potocnik U., Ferkolj I., Glavac D. et al. Polimorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn's disease and ulcerative colitis. Genes Immun. 2004, v. 5, p. 530-539.
  18. Onnie СМ., Fisher S A., Pattni R. et al. Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behavior: a case-control and meta-analysis study. Inflamm Bowel Dis. 2006, v. 12 (4), p. 263-271.
  19. Annese V., Valvano M. R., Palmieri О. et al. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J. Gastroenterol. 2006, v. 12, p. 3636-3644.
  20. Ardizzone S., Maconi G, Bianchi V. et al. Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease. Inflamm. Bowel Dis. 2007, v. 13, p. 516-523.
  21. Бэрева О.Б., Бришанова А.Ю., Мухин О.В. Возможный прогноз эффективности химиотерапии больных лимфо-пролиферативными заболеваниями в зависимости от G2677T и С3435Т полиморфизмов гена MDR1. Бюлл. эксп. биол. 2003, № 8, с. 209-212.
  22. Бэрева О.Б., Бришанова А.Ю., Домникова Н.П. Полиморфизм С1236Т гена MDR1 в Российской популяции: ассоциации с предрасположенностью к лимфопролифе-ративным заболеваниям и устойчивостью к химиотерапии. Бюлл. эксп. биол. 2004, № 10, с. 454-457.
  23. Стюф И.Ю., Быкова Т.В., Зарицкий АЮ. Биперэкспрессия гена множественной лекарственной устойчивости (MDR-1) у больных хроническим миелолейкозом. Тер. арх. 1998, № 7, с. 26-29.
  24. Maggini V, Buda G, Martino A. et al. MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet Genomics. 2008, v. 18 (5), p. 383-389.
  25. MatternJ. Drug resistance in cancer: a multifactorial problem. Anticancer Res. 2003, v. 23 (2C), p. 1769-1772.
  26. Thomas H. and Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control. 2003, v. 10, p. 159-165.
  27. Sawicka M., Kalinowska M., Skierski J., Lewandowski W A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence. J. Pharm. Pharmacol. 2004, v. 56, p. 1067-1081.
  28. Smyth M.J., KrasovskisE., Sutton V.R, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc. Natl. Acad. Sci. USA. 1998, v. 95, p. 7024-7029.
  29. Johnstone R.W, Cretney E., Smyth M.J. P-Glycoproteinprotects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood. 1999, v. 93, p. 1075-1085.
  30. Zarickii A.U., Bikova TV, Lomaia E.G. et al. K-562 transfected with MDR-1 gene are less sensitive than parental cells to interferon-alpha induced inhibition of cell proliferation. Acta Haematologyca, 1998, v. 100 (1), p. 231.
  31. Зубова СТ., Данилов А.О., Мышков А.И. и соавт. Ген MDR1 и чувствительность клеток к различным воздействиям. Вопр. онкологии. 2000, т. 46, № 2, с. 199.
  32. Pawlik A., Wrzesniewska J, Fiedorowicz-Fabrycy L, Gawronska-Szklarz В. The MDRl 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol Ther. 2004, v. 42 (9), p. 496-503.
  33. СычевД.А. Значение полиморфизма гена MDRl, кодирующего гликопротеин-Р, для индивидуализации фармакотерапии. Клин, фармакол. и тер. 2005, № 1, с. 92-96.
  34. Pawlik A., Baskiewicz-Masiuk M., Machalinski В. et al. Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexametha-sone. Eur J. Pharmacol. 2005, v. 28, p. 27-36.
  35. Marthinet E., Divita G., Bernaud J. et al. Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDRl promoter. Gene. Ther. 2000, v. 7 (14), p. 1224-1233.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2009



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies